BridgeBio Oncology Therapeutics, Inc. (BBOT)
Health Care · biotechnology · NASDAQ
A clinical-stage oncology firm developing next-generation small-molecule inhibitors to target RAS and PI3K-driven cancers through monotherapy and combination strategies.
What BridgeBio Oncology Therapeutics, Inc. does
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel small-molecule therapeutics to treat cancers driven by RAS and PI3K pathways. The company is currently advancing three lead product candidates, including inhibitors that target KRAS G12C, pan-KRAS mutations, and the interaction between RAS and PI3Kα.
Recent developments
The company initiated internal combination studies for BBO-8520 and BBO-11818 with BBO-10203 in 2026. Management reported a cash runway sufficient to fund operations into 2028.
From BridgeBio Oncology Therapeutics, Inc.'s filing of 2026-08-11.
Themes: oncology, RAS pathway inhibitors, KRAS mutations, PI3K pathway inhibition, precision medicine
Fundamentals
- Price$2.72 as of 2026-10-20 close
- Market cap$218M as of 2026-08-06 (share count; price 2026-10-20)
- 1-year return-75.8% 2025-10-20 close $11.25 → 2026-10-20 close $2.72
- P/En/a negative earnings
- ROE-32.6% FY2025, SEC XBRL
- ROICn/a No figure: its 10-K tags no pre-tax income, so no tax rate can be taken.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta0.43 as of 2026-09-03
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How BBOT compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$60M | -$56M | -$705.20 | -$44M† | $47000† |
| Q1 FY2026 2026-03-31 | -$46M | -$42M | -$526.11 | -$36M | $24000 |
| Q4 FY2025 2025-12-31 | -$43M† | -$39M† | $2.19† | -$42M† | $73000† |
| Q3 FY2025 2025-09-30 | -$49M | -$45M | -$1.03 | -$29M† | $140000† |
| Q2 FY2025 2025-06-30 | -$30M | -$28M | -$566.46 | -$23M† | $231000† |
| Q1 FY2025 2025-03-31 | -$23M | -$22M | -$54.23 | -$20M | $162000 |
| Q4 FY2024 2024-12-31 | -$22M† | -$20M† | -$833.69† | -$15M† | $10000† |
| Q3 FY2024 2024-09-30 | -$20M | -$17M | -$1562.18 | -$39M† | — |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$54M
- Short-term investments$172M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How BridgeBio Oncology Therapeutics, Inc. looks technically
BridgeBio Oncology Therapeutics, Inc. (BBOT) is trading 68.8% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 142 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 59, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 15, in oversold territory (below 30). It just made a new 20-day low, breaking below its recent trading range. It is 0.7% above its 52-week low (its lowest price of the past year).
Trend
7
| Distance from the 200-day | it is trading 68.8% below its 200-day average, the long-term trend line — a long-term downtrend | -68.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $6.04 | $6.04 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $8.71 | $8.71 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 50 calendar days ago — the swings before that are what the structure reading is measured on | 50 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 142 trading days ago — a "death cross", a bearish long-term signal | 142 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 59, with sellers in control | 59.1 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 15, in oversold territory (below 30) | 15.2 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($2.70 to $4.10) — its "stochastic" reading is 1 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 1.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $14.87 | $14.87 |
|---|---|---|
| From the 52-week high | it is 81.7% below its 52-week high (its highest price of the past year) | -81.7% |
| Above the 52-week low | it is 0.7% above its 52-week low (its lowest price of the past year) | +0.7% |
| Below the 52-week high | it is 81.7% below its highest point of the past year | 81.7% |
| Since a 20-day breakout | it just made a new 20-day low, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $14.87 (set on 2025-12-08) | $14.87 |
| Given back of the 52-week move | over the past year its closes ranged ($2.72 to $13.73), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $9.52 to $9.88. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 81.7% below its all-time high | -81.7% |
| Nearest price level | it is trading 195.1% below a resistance level at $8.03 — a price it turned at four times since 2026-04-07, most recently on 2026-08-03. Since 2024-10-21 it has 0 such levels below the current price and 14 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +195.1% |
| All-time low | its lowest closing price on record is $2.70 (set on 2026-10-20) | $2.70 |
| Above the all-time low | it is 0.7% above its all-time low | +0.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 81% of the past ~6 months) | 81st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3008 between its high and its low — about 11.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3008 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.54 and $4.41 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.54 – $3.47 – $4.41 |
| Typical daily range (% of price) | its price moves about 11.1% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 11.1% |
| Stretch from the 200-day average | it is trading 19.9 daily ranges below its 200-day average price (68.8% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 19.9 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.91× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
4
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a hammer | 8 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 8 sessions ago |
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
| Since a bearish engulfing | today it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | today |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Gap filled | a 2.4% gap up opened on 2026-08-19 has been "filled" 40 sessions ago — price traded back through the level the gap left behind, and it took 3 sessions to close | 40 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 43.9 percentage points (the stock lost 43.0% while the market gained 1.0%) | -43.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 71.3 percentage points (the stock lost 67.7% while the market gained 3.6%) | -71.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 79.1 percentage points (the stock lost 70.6% while the market gained 8.5%) | -79.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 90.4 percentage points (the stock lost 75.8% while the market gained 14.6%) | -90.4% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), MACD momentum is positive, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 62% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 5.5% of the share price. | -62.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 66% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $7.91 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -65.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 48% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $5.25 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -48.2% |
Price levels it has turned at before
BBOT last closed at $2.72 on 2026-10-20. Since 2024-10-21 it has turned at 0 prices below its last close and 14 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $8.03 | Resistance | 195.1% above the last close | turned there four times · 2026-04-07 to 2026-08-03 |
| $8.46 | Resistance | 210.8% above the last close | turned there twice · 2025-08-05 to 2026-08-31 |
| $8.74 | Resistance | 221.5% above the last close | turned there three times · 2025-08-13 to 2026-08-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Oversold (14-day RSI below 30) · Near the 52-week low · Pulled back from the 12-month high · Broke down to a new 20-day low | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$24.55 range $15.00 – $50.00; median $22.00
Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BBOT
- Consensus EPS estimate-$0.6588 next reporting period, as of 2026-10-20
- Estimate change, 30 days$0.00 from -$0.6588, on 2026-09-15, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with no products approved for commercial sale and a history of significant operating losses.","Development of product candidates is speculative, and failure in preclinical studies or clinical trials would materially harm the business.","Substantial additional funding will be required to support long-term operations, creating potential dilution or financing risks."]
What changed in the latest 10-Q
AI-assisted comparison of BBOT's 10-Q filed 2026-08-11 against the prior one filed 2026-05-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing states financial results for the three and six months ended June 30, 2026 and 2025; older filing states results for the three months ended March 31, 2026 and 2025.
- Newer filing reports a net loss of $56.5 million for the three months ended June 30, 2026 and $98.6 million for the six months ended June 30, 2026; older filing reports a net loss of $42.1 million for the three months ended March 31, 2026.
- Newer filing reports an accumulated deficit of $455.1 million as of June 30, 2026; older filing reports an accumulated deficit of $398.7 million as of March 31, 2026.
- Newer filing states that an internal combination study with BBO-10203 opened in July 2026 for BBO-11818.
- Newer filing includes statement that updated clinical data for BBO-10203 are expected in the second half of 2026 without additional combination study opening language included in older filing.
- Removed:
- Older filing includes detailed January 7, 2026 preliminary clinical data for BBO-8520 monotherapy, including a 65% objective response rate (ORR), 68% 6-month progression-free survival (PFS), 83% of patients eligible for 6-month follow-up remaining on treatment for ≥6 months, and partial responses in all five initial KRASG12C and STK11 and/or KEAP1 co-mutant patients.
- Older filing includes January 7, 2026 preliminary clinical data for BBO-11818, including encouraging early anti-tumor activity across dose levels and tumor types, a PR in a PDAC patient with a 56% tumor reduction, and generally tolerable monotherapy with no dose-limiting toxicities.
- Older filing includes January 7, 2026 preliminary clinical data for BBO-10203, including differentiated safety profile with no hyperglycemia, target systemic exposure and rapid full target engagement, and clinical benefit in CRC and HR+ breast cancer patients.
- Older filing includes April 2026 AACR Annual Meeting preclinical data presentations for BBO-11818 and BBO-10203.
- Older filing includes March 2026 announcement of appointment of Peter Lebowitz, M.D., Ph.D. as a member of the board of directors.
- Older filing includes April 2026 announcement of appointments of Neil Kumar, Ph.D. as Executive Chairman, Pedro J. Beltran, Ph.D. as CEO, Idan Elmelech as COO, and Marc Cobo as Principal Accounting Officer, effective April 20, 2026, and statement that former CEO Eli Wallace, PhD will serve as Senior Adviser.
- Reworded:
- Newer filing describes BBO-11818 internal combination study with BBO-10203 as having opened in July 2026; older filing states it was anticipated to open later in 2026.
- Newer filing removes the specific clinical data updates announced on January 7, 2026 for all three product candidates that were present in older filing.
- Newer filing omits the leadership appointment announcements included in older filing.
- Notes:
- Newer filing text appears truncated at the phrase 'we would be required to expend significant additional financial resources'; the full newer MD&A section may contain additional content not provided.
- Older filing text appears truncated at 'Our ability to generate sufficient product revenue to achieve profitability will depend heavily on the development and eventual commercialization ef'; the full older MD&A section may contain additional content not provided.
- Comparison is limited to the provided excerpt of each filing.
Risk Factors
- Added:
- Newer filing (2026-08-11) adds a new risk factor bullet: "We may seek certain designations for our product candidates, including Breakthrough Therapy, Fast Track and Priority Review in the U.S., and PRIME (priority medicines) in the EU, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process." This bullet is not present in the older filing (2026-05-12).
- Reworded:
- The summary risk factor bullet about limited operating history changed from "BBOT has a limited operating history..." (older, filed 2026-05-12) to "We have a limited operating history..." (newer, filed 2026-08-11).
- The bullet about ability to generate revenue changed from "BBOT's ability to generate revenue..." (older) to "Our ability to generate revenue..." (newer).
- The bullet about requiring additional capital changed from "BBOT may require additional capital..." (older) to "We may require additional capital..." (newer).
- The bullet about preclinical studies and clinical trials changed from "BBOT's preclinical studies..." (older) to "Our preclinical studies..." (newer).
- The bullet about delays in clinical trials changed from "BBOT's current, planned or future clinical trials..." (older) to "our current, planned or future clinical trials..." (newer).
- The bullet about outcome of preclinical testing changed from "the results of BBOT's clinical trials..." (older) to "the results of our clinical trials..." (newer).
- The bullet about regulatory approval processes changed from "If BBOT is ultimately unable to obtain regulatory approval..." (older) to "If we are ultimately unable to obtain regulatory approval..." (newer).
- The bullet about product candidates causing adverse events changed from "BBOT's product candidates may cause..." (older) to "Our product candidates may cause..." (newer).
- The bullet about reliance on third parties for supply and manufacture changed from "BBOT currently relies..." (older) to "We currently rely..." (newer).
- The bullet about competition changed from "BBOT faces substantial competition..." (older) to "We face substantial competition..." (newer).
- The bullet about third-party coverage and reimbursement changed from "Any product candidates BBOT develops..." (older) to "Any product candidates we develop..." (newer).
- The bullet about product liability changed from "BBOT's business entails..." (older) to "Our business entails..." (newer).
- The bullet about regulatory approval in one jurisdiction changed from "BBOT's product candidates..." (older) to "our product candidates..." (newer).
- The bullet about data privacy laws changed from "BBOT is or may become subject..." (older) to "We are or may become subject..." (newer).
- The bullet about success dependent on attracting employees changed from "BBOT's success is highly dependent on BBOT's ability..." (older) to "Our success is highly dependent on our ability..." (newer).
- The bullet about patent protection changed from "If BBOT is unable to obtain, maintain and enforce patent protection..." (older) to "If we are unable to obtain, maintain and enforce patent protection..." (newer).
- The bullet about patent terms changed from "BBOT's competitive position..." (older) to "our competitive position..." (newer).
- The bullet about patent lawsuits changed from "BBOT may become involved in lawsuits..." (older) to "We may become involved in lawsuits..." (newer).
- The bullet about reliance on third parties for preclinical studies and clinical trials changed from "BBOT relies on third parties..." (older) to "We rely on third parties..." (newer).
- The bullet about active trading market changed from "There may not be an active trading market for our Common Stock..." (older) to "There may not be an active trading market for our common stock..." (newer).
- The bullet about future sales changed from "by the Company or its stockholders..." (older) to "by us or our stockholders..." (newer).
- The bullet about material weakness changed from "If BBOT identifies additional material weaknesses..." (older) to "If we identify additional material weaknesses..." (newer).
- The bullet about increased costs as a public company changed from "BBOT has increased costs..." (older) to "We have increased costs..." (newer).
- The bullet about economic uncertainty changed from "...significantly impacted by a new U.S. presidential administration and accompanying regulatory activities and economic policies and events related thereto, ongoing military conflicts and geopolitical instability and inflation and interest" (older) to "...significantly impacted by changes in regulatory activities and economic policies and events related to the current U.S. presidential administration, ongoing military conflicts and geopolitical instability and inflation and interest rates." (newer).
- Notes:
- The provided texts are excerpted and truncated; the newer filing's Risk Factors section ends mid-sentence at "We have a limited operating history, have" and the older filing ends at "...inflation and interest" without closing the bullet. Only changes visible within the provided excerpts are reported.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for BBOT — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding BBOT as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 8,725,450
- Reported value $66,487,927
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about BBOT's institutional holders → See what each manager we track holds →
Short interest (FINRA)
BBOT had 3,374,885 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
BBOT had 4.21% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.4 days to cover at the same settlement.
- Reported short interest (shares) 3,374,885
- Short interest (% of shares outstanding) 4.21%
- Prior settlement (shares) 3,595,979
- Reported change -6.15%
- Days to cover (reported) 5.4
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Mirati Therapeutics (acquired by Bristol Myers Squibb) (BMY)
- Revolution Medicines (RVMD)
- Verastem Oncology (VSTM)
- Erasca (ERAS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BBOT vs…
BridgeBio Oncology Therapeutics, Inc. is found in…
Frequently asked questions
What does BridgeBio Oncology Therapeutics, Inc. (BBOT) do?
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel small-molecule therapeutics to treat cancers driven by RAS and PI3K pathways. The company is currently advancing three lead product candidates, including inhibitors that target KRAS G12C, pan-KRAS mutations, and the interaction between RAS and PI3Kα.
What sector is BridgeBio Oncology Therapeutics, Inc. (BBOT) in?
BridgeBio Oncology Therapeutics, Inc. (BBOT) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are BridgeBio Oncology Therapeutics, Inc.'s (BBOT) competitors?
Notable peers of BridgeBio Oncology Therapeutics, Inc. (BBOT) include Amgen, Mirati Therapeutics (acquired by Bristol Myers Squibb), Revolution Medicines, Verastem Oncology and Erasca. This peer set is informational only — not financial advice.
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) overbought or oversold right now?
BridgeBio Oncology Therapeutics, Inc. (BBOT) is currently in oversold territory (its 14-day RSI is 15, below 30) (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BBOT come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.